Abstract
Regulatory T cells affect the transcriptional programs of key accessory cells in the tumor microenvironment.
Major Finding: Regulatory T cells affect the transcriptional programs of key accessory cells in the tumor microenvironment.
Concept: VEGF blockade combined with regulatory T-cell depletion strategies improves tumor control and survival.
Impact: These results can be used to inform new combination strategies for the treatment of solid tumors.
Regulatory T (Treg) cells have immunosuppressive functions, and their depletion has been shown to restrain tumor growth across many cancer models. These cells have typically been shown to suppress antigen-presenting cells as well as effector T cells, but recent studies have indicated that a wider range of cell types may be affected by Treg cell functions. To determine the connection between Treg cells and other cell types within the tumor microenvironment (TME), Glasner, Rose, Sharma, and colleagues evaluated the immediate changes to the single-cell transcriptomes of accessory cells within the TME using temporally controlled deletion of Treg cells in murine lung cancer models. Alterations to the transcriptional programs of endothelial cells, fibroblasts, and macrophages were observed 48 hours after Treg depletion, and gene expression programs related to IFN response, inflammatory cytokines (IC), and IL6 signaling were shared between accessory cells. Moreover, similar phenotypes were observed in an injury model of fibrotic lung inflammation, suggesting that these phenotypes are shared across pathologic conditions. Evaluation of the spatial distribution of accessory cell types revealed two distinct signaling niches in the tissue, with the IC gene program being clustered to the tumor core, while the IFN response gene program was localized to the periphery of tumor lesions, supporting the notion that the response to Treg depletion is spatially restricted. Additionally, Treg cell–dependent gene expression patterns, including VEGF and CCR2 signaling–related genes, were found to be conserved between mouse and human lung adenocarcinoma, which highlighted compensatory pathways that could be potentially targeted along with Treg depletion strategies. Accordingly, as proof of concept, depletion of Treg cells in combination with a VEGF neutralizing antibody in murine lung tumor cells resistant to PD-1 blockade demonstrated greater tumor reduction and improved overall survival as compared to no treatment or either single agent alone. In summary, this study shows that Treg cells impact many cells within the TME and suggests that targeting these interdependent networks can be exploited in the development of new therapeutic strategies.
Note:Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.